Monoclonal antibody and vaccine targeting filamentous bacteriophage
Inventors
Bollyky, Paul L. • Parks, William • Secor, Patrick
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10835607-B2
Publication Date
2020-11-17
Expiration Date
Abstract
Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
Core Innovation
The invention relates to treating or preventing Pseudomonas aeruginosa biofilm formation by administering an antigen-binding polypeptide that binds Pf-family bacteriophage, including Pf4 bacteriophage, and/or by administering a vaccine targeting Pf-family phage. The disclosed antigen-binding polypeptides include monoclonal antibodies and antibody fragments, directed to the Pf4 CoaB coat protein and antigenic fragments thereof.
The disclosed embodiments include antibodies directed to the Pf4 CoaB coat protein, including antigenic fragments, and provide an immunogenic peptide consisting of the amino acid sequence of SEQ ID NO: 1, conjugated to an immunogenic protein. The immunogenic composition includes a pharmaceutically acceptable carrier, and the antibodies can be of antibody isotypes including IgG or IgM.
The disclosure further connects anti-CoaB/anti-Pf4 antibody activity with disruption of liquid-crystalline biofilm organization, reduction of antibiotic tolerance, and improvement of antibiotic penetration. It also encompasses vaccine and pharmaceutical composition concepts, including immunogenic CoaB fragments and immunogenic compositions formulated with carriers, as well as polynucleotide and expression construct concepts for producing antibody-related components.
Claims Coverage
The document provides coverage centered on an immunogenic composition having a CoaB peptide from a Pf4-family bacteriophage. The independent claim contains 2 main inventive elements: a pharmaceutically acceptable carrier with a defined immunogenic peptide from Pf4-family CoaB, and a requirement that the peptide (SEQ ID NO: 1) is conjugated to an immunogenic protein. A dependent claim refines this by defining an administering-based method to elicit an immune response against Pf4-family bacteriophage in animal or human subjects.
CoaB peptide immunogenic composition with SEQ ID NO: 1 and pharmaceutically acceptable carrier
An immunogenic composition comprising a pharmaceutically acceptable carrier and an immunogenic peptide of CoaB protein of Pf4-family bacteriophage, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 1.
Conjugation of SEQ ID NO: 1 CoaB peptide to an immunogenic protein
The immunogenic peptide of the CoaB protein (SEQ ID NO: 1) is conjugated to an immunogenic protein.
Administering immunogenic composition to elicit immune response against Pf4-family bacteriophage
A method of eliciting an immune response against Pf4-family bacteriophage by administering the immunogenic composition to an animal or human subject.
Overall, the claim set focuses on an immunogenic composition that presents a defined Pf4-family CoaB peptide (SEQ ID NO: 1) with a pharmaceutically acceptable carrier, where the peptide is conjugated to an immunogenic protein, and a related method of administering the composition to elicit an immune response against Pf4-family bacteriophage.
Stated Advantages
Disrupts liquid-crystalline biofilm organization.
Reduces antibiotic tolerance.
Improves antibiotic penetration.
Documented Applications
No documented applications found
Interested in licensing this patent?